HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Ralph A. Schmid Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stammberger, U. Articles by Schmid, R. A. Search for Related Content PubMed PubMed Citation Articles by Stammberger, U. Articles by Schmid, R. A. Related Collections Lung - transplantation

Eur J Cardiothorac Surg 2002;22:368-372
© 2002 Elsevier Science NL

sCR1sLe^X reduces lung allograft ischemia–reperfusion injury but does not ameliorate acute rejection

^a Division of General Thoracic Surgery, University Hospital Berne, 3010 Berne, Switzerland
^b Biochemical Pharmacology, University of Konstanz, Konstanz, Germany
^c Department of Pathology, University Hospitals Geneva, Geneva, Switzerland

Received 19 September 2001; accepted 31 May 2002.

* Corresponding author. Tel.: +41-31-632-23-30; fax: +41-31-632-23-27
e-mail: ralph.schmid{at}insel.ch

Background: Combined inhibition of complement and leukocyte adhesion by sCR1sLe^X reduces lung allograft dysfunction up to 24 h. In the present study its effect on graft function and acute rejection was evaluated up to 5 days after experimental transplantation. Methods: Orthotopic single left lung transplantation was performed in 35 male rats (Brown Norway to Fischer 344) after a total ischemic time of 20 h. Two groups were assessed after 1, 3, and 5 days post-transplant, respectively (n=5 per group and time point): controls vs. recipients which received 10 mg/kg sCR1sLe^X 15 min prior to reperfusion. In addition, five animals received 10 mg/kg per day sCR1sLe^X for 5 days. For blood gas analysis of the graft, the contralateral lung was occluded for 5 min to assess graft function. Lung grafts were flushed, and histological grading was performed in blinded fashion according to the International Society for Heart and Lung Transplantation criteria. Results: Graft PaO₂ in recipients treated with sCR1sLe^X was superior on day 1 (383±118 vs. 56±15 mmHg; P<0.0001) and day 3 (446±48 vs. 231±108 mmHg; P<0.0001). Five days after transplantation, no difference in PaO₂ was found (61±28 vs. 83±31 mmHg; P=0.59). Repeated treatment with sCR1sLe^X for 5 days did not improve PaO₂ (64±5 mmHg; P=0.65 vs. control; P=0.93 vs. sCR1sLe^X). At any time point, there was no difference in the degree of rejection between groups. Conclusions: In this model sCR1sLe^X provided marked improvement of graft function up to 3 days, but inhibition of both complement system and selectin dependent leukocyte adhesion failed to protect against acute rejection.

Key Words: sCR1sLe^X • Lung transplantation • Reperfusion injury • Graft rejection • Models • Animal • Complement

This article has been cited by other articles:

				N. Geudens, M. Van de Wouwer, B. M. Vanaudenaerde, R. Vos, C. Van De Wauwer, G. M. Verleden, E. Verbeken, T. Lerut, D. E. M. Van Raemdonck, and E. M. Conway The lectin-like domain of thrombomodulin protects against ischaemia-reperfusion lung injury Eur. Respir. J., October 1, 2008; 32(4): 862 - 870. [Abstract] [Full Text] [PDF]

				U. Stammberger, B. Kubisa, M. Gugger, E. Ayuni, R. Claudio, T. Grodzki, and R. A. Schmid Strong additive effect of 1,25-dihydroxycholecalciferol and cyclosporine A but not tacrolimus in rat lung allotransplantation Eur. J. Cardiothorac. Surg., August 1, 2003; 24(2): 196 - 200. [Abstract] [Full Text] [PDF]